Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 40INDUSTRY 15NIH 5OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia 3Burkitt Lymphoma 3Solid Tumors 1Solid Tumor 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited 1

Interventions

Nivolumab 2fludarabine 1eltrombopag 1avelumab 1Immunotherapy, Adoptive 1Cyclophosphamide 1CTL019 chimeric antigen receptor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Lymphoma, B-Cell × fludarabine × Clear all
NCT03101709 2017-04-05

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Henan Cancer Hospital

Phase 1 Unknown
30 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡